

Asthma & Obstructive Sleep Apnea

Sushma Dharia, MD, FCCP, FAASM, ATSF

Sushma.Dharia@va.gov

Department of Internal Medicine,
Veterans Health Care System of the Ozarks, Fayetteville, AR

Adjunct Clinical Assistant Professor,
University of Arkansas for Medical Sciences

Sleep Professionals of Arkansas
Annual Educational Meeting
9-March-2024

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Academy of Sleep Medicine and the Sleep Professionals of Arkansas & Washington Regional Center for Sleep Disorders. The American Academy of Sleep Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Conflict of Interest Disclosures for Speakers

Sushma Dharia, MD, FCCP, FAASM, ATSF has no relevant financial relationships with ineligible companies to disclose.

Learning Objectives

Upon completion of this course, attendees should be able to ...

1. Describe mechanisms for Asthma and Obstructive Sleep Apnea
2. Understand link between OSA and Asthma
3. Evaluate treatment and management options

Agenda

- Definitions (OSA, OLD, Asthma)
- Prevalence
- Pathophysiology
- Overlap syndrome (OSA-OLD)
 - Bi-directional relationships
 - Predispositions
- Alternative overlap syndrome (OSA-Asthma)
 - Bi-directional relationships
 - Bi-directional Impact
 - Rx effects
- Findings from select studies
- Summary & Recommendations

Obstructive Respiratory Events


- Apnea
 - cessation of ventilation for 10 seconds or longer
- Hypopnea
 - decrease in ventilation, and
 - oxyhemoglobin desaturation
 - or
 - terminated by arousal
- “Upper Airway Resistance Event” or “Respiratory Effort Related Arousal” (obstructive)
 - increased respiratory effort
 - no change in ventilation
 - terminated by arousal
- Snoring: *The sound produced by the soft tissues of the upper airway, primarily the pharynx, soft palate, and uvula, when turbulent airflow causes these tissues to vibrate*

What is OSA?

- Obstructive Apneas, Hypopneas
 - Repeated episodes of collapse of pharyngeal airway, usually a result of obstruction by soft tissue in the rear of throat



Normal Airway




Obstructed Airway

Obstructive Events: The Continuum




Worsening Disease →
Decreasing Airway Caliber →


Site of Obstruction in OSA by Sleep Endoscopy



Endoscopic Appearance of Oropharyngeal Collapse




Antero-posterior



Lateral

Bachar G et al. Eur Arch Otorhinolaryngol 2008



Antero-posterior




Concentric

10 Vicini C et al. Eur Arch Otorhinolaryngol 2012

Vicini C et al. Eur Arch Otorhinolaryngol 2012


Normal vs. OSAS Airway: Sagittal View

Normal Subject




Mandible
Tongue
Soft Palate

Apneic Patient




Mandible
Tongue
Soft Palate

Normal vs. OSAS Airway: Transverse View



Airway size and orientation both correlate with OSA

OSA Pathophysiology



**Nasal airway occlusion test
during sleep in OSA patient**

Issa et al., J Appl Physiology, 57(2):520-527, 1984

OSA Prevalence


- 14% - 26% of population has OSA

Benjafield AV, et al. *Lancet Respir. Med.* 2019; 7: 687–98;
American Academy of Sleep Medicine, 2014

- OSA is still grossly underdiagnosed
 - Large French population-based cohort (n=20,151)
 - 1 in 5 has high likelihood of OSA (20%)
 - Only 3.5% are diagnosed for OSA

Balagny P, et al. *ERJ Open Res* 2023; 9: 00053-2023

Sleep Deficit Prevalence



Age Group	Recommended Hours of Sleep Per Day
Newborn	0-3 months 14-17 hours (National Sleep Foundation) ¹ No recommendation (American Academy of Sleep Medicine) ²
Infant	4-12 months 12-16 hours per 24 hours (including naps) ²
Toddler	1-2 years 11-14 hours per 24 hours (including naps) ²
Preschool	3-5 years 10-13 hours per 24 hours (including naps) ²
School Age	6-12 years 9-12 hours per 24 hours ²
Teen	13-18 years 8-10 hours per 24 hours ²
Adult	18-60 years 7 or more hours per night ³
	61-64 years 7-9 hours ¹
	65 years and older 7-8 hours ¹

CDC Behavioral Risk Factor Surveillance System (BRFSS), 2013, 2014, 2016, 2018, 2020

Obstructive Lung Disease (OLD)

- OLD includes distinct sub-phenotypes:


- Chronic bronchitis
 - Emphysema
- } COPD

- Asthma with airway hyperreactivity
 - Asthma with remodeling and no airflow reversibility
 - Small airway disease
- } ASTHMA

- Disease phenotypes often overlaps

OSA & Comorbidities


Bidirectional Relationships



Gleeson et al, Eur Respir Rev 2022; 31: 210256

COPD


- Definition: A group of diseases that cause airflow blockage and breathing-related problems. It includes **emphysema** and **chronic bronchitis**.



- **Chronic Bronchitis**: cough & sputum production for >3 months; ≥ 2 consecutive years
- **Emphysema**: Permanent enlargement and destruction of walls in distal air spaces


COPD Prevalence

- About 16 million people in the United States has COPD and trend is unchanged during 2011-2022.



CDC Behavioral Risk Factor Surveillance System (BRFSS), 1999-2011
 Ford et al, CHEST 2013; 144(1):284 –305

7%



CDC Behavioral Risk Factor Surveillance System (BRFSS), 2011-2020

Asthma

- Definition: A condition in which a person's airways become inflamed, narrow and swell, and produce extra mucus, which makes it difficult to breathe.
- Causes variable and recurrent episodes of wheezing, breathlessness, chest tightness, cough – especially at night or early morning

- Prevalence:

- About 1 in 13 people in the United States has asthma, according to the Centers for Disease Control and Prevention.


8%

NHIS, 2021

- 26 million people in United States has physician-diagnosed asthma, costs US economy about \$82 billion in 2013 alone

Yoghoubi, AJRCCM 2019 (200-9)

Asthma Prevalence




CDC BRFSS Prevalence & Trends Data 2022


Bronchospasm constricts the airway



Normal Airway




Asthmatic Airway



Cleveland Clinic


Ophea Asthma Friendly website (CA)

Interplay and Interaction between Airway Inflammation and Clinical Symptoms and Pathophysiology of Asthma



NHLBI Asthma Guidelines, EPR-3, Aug 2007

Asthma - Pathophysiology



Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults, *The Lancet*, 2006 Aug 26;368(9537):780-93

Asthma - Pathophysiology

Airflow limitation in asthma is recurrent and caused by a variety of changes in the airway:

- **Bronchoconstriction:** airway narrowing interfering with airflow. Bronchoconstriction narrows the airways in response to exposure to a variety of stimuli
- **Airway edema:** further limits airflow
- **Airway hyperresponsiveness:** an exaggerated bronchoconstrictor response to a wide variety of stimuli
- **Airway remodeling:** Permanent structural changes can occur in the airway; Associated with a progressive loss of lung function that is not prevented by current therapy

Asthma is not COPD


- They have different:
 - etiology;
 - symptoms;
 - type of airway inflammation;
 - inflammatory cells;
 - mediators;
 - consequences of inflammation;
 - response to therapy;
 - course.

ASTHMA and COPD		
	ASTHMA	COPD
Cause:	sensitive agent	noxious agent (mainly cigarette smoking)
	Asthmatic airway inflammation (CD4+T-lymphocytes and Eosinophils)	COPD airway inflammation (CD8+T-lymphocytes, Macrophages and Neutrophils)
	Reversible	Not fully reversible
	AIRFLOW LIMITATION	

Cukic et al, Mat Soc Med. 2012 Jun; 24(2): 100-105

OLD Overlap with OSA

- OSA features bi-directional interaction with OLD
 - Complex interaction between COPD, Asthma, OSA
 - Contribution of Smoking, Obesity, GERD



Ioachimescu et al, *Respirology* (2013) 18, 421-431

OLD ↔ OSA

- Clinic population study:
 - N=67 OLD patients (57% COPD, 43% Asthma), Mean FEV₁ = 71%
 - N=75 Control group
 - OSA risk was higher for COPD group (50% vs 7.5% for control)
 - OSA risk higher for Asthma group (62% vs 7.5% for control)
 - PSG (n=26 high risk OSA)
 - 24 diagnosed with OSA (92% predictivity using BQ)
 - Mean AHI 17.1/h; Predominantly REM related AHI in 61.5%
- Urban outpatients in pulmonary clinic with OLD are very frequently at high risk for OSA

Sharma et al, Lung. 2011; 189(1): 37-41

OLD ↔ OSA

- Patients with overlap syndrome has ↑ risk of morbidity and mortality (compared to COPD or OSA alone)
- Nocturnal hypoxaemia ↑ as COPD patients do not return to normal O₂ saturation levels
 - Leads to pulmonary HTN and cor pulmonale
 - Prevalence of cor pulmonale in overlap syndrome patients is 80% with 30% 5-year survival
- Overlap syndrome patients had \$4,155 more in Medicaid claims than COPD alone
- CPAP+O₂ → 5-year survival of 71% (versus 26% with O₂ alone)

Rasche et al, Internist (Berl) 2007; 48: 276–82

Shaya et al, Sleep Breath. 2009; 13: 317–23

Machado et al, Eur. Respir. J. 2009; 35: 132–7

OLD ↔ OSA

Pathophysiology

- COPD and OSA may exacerbate each other due to commonalities:
 - Aging, Smoking, vagal tone ↑, GERD, Hypoxia, pulmonary HTN, Endothelial dysfunction, inflammatory state
- Smoking
 - → Sleep Q ↓
 - → expiratory flow limitation ↑
 - → upper airway collapse ↑ & Obesity ↑


OLD → OSA Pathophysiology

- COPD → Corticosteroid ↑
- → Fat deposition in neck ↑
- → abdominal fat effect on diaphragm ↑
- → Upper airway closure ↑

Ioachimescu et al, *Respirology* (2013) 18, 421-431

OSA ↔ OLD


Bi-directional Relationship



Gleeson et al, Eur Respir Rev 2022; 31: 210256


COPD: Comorbidity of Asthma

- 12,743 asthmatics, study at 187 centers in Hungary




COPD: Comorbidity of Asthma

- COPD presence: high for partially controlled asthma



COPD: Comorbidity of Asthma

- COPD presence: higher for uncontrolled asthma



Tomisa et al, *Allergy Asthma Clin Immunol* (2021)17-95

Asthma & OSA

Alternative Overlap Syndrome

- 35% prevalence of OSA in asthmatics
- Both OSA & Asthma are highly prevalent disease
 - Coexists in some patients

Kong et al, Scientific Report 2017; 7-4088

- Have overlapping comorbidities
 - GERD, rhino sinitis, obesity

Kasabef et al, Sleep Med Rev 2007; 11(1):47-58

Asthma → OSA

Pathophysiology

- GERD (commonly encountered with Asthma)
 - Proximal migration of gastric acid & prolonged acid clearance during sleep → Pharyngeal spasm & mucosal exudative neurogenic inflammation → upper airway dysfunction and prone to collapse during sleep

Harding et al, Immunol. Allergy Clin. North Am. 2005; 25: 131–48; Orr WC et al, Am. J. Gastroenterol. 2000; 95: 37–42

- Corticosteroids → upper airway patency
 - Local myopathy of its dilators (muscle fiber atrophy)
 - Regional fat accumulation around upper airway due to systemic absorption


Shibley et al, Sleep 1992; 15: 514–8; Donnelly et al, Am. J. Respir. Crit. Care Med. 1997; 156: 1746–51;

Martin RJ et al, Am. J. Respir. Crit. Care Med. 2002; 165: 1377–83

Asthma → OSA

Pathophysiology

- Asthma's pathognomonic features, notably airway and systemic inflammation, could destabilize peripheral and central breathing and upper-airway control mechanisms.
- In conjunction with anatomical effects of long-term inhaled corticosteroid (ICS) therapy on the pharyngeal airway, it sets the stage for upper-airway collapse during sleep and OSA.



Asthma → OSA

- Correlation of Asthma causing OSA is not well established.
- Evidence is based on observational studies.
- However, the evidence is quite overwhelming.

Asthma → OSA

Impact

- Wang et al Meta-analysis
 - 34 studies with 27,912 subjects were included.
 - OSA was associated with more severe or difficult-to-control asthma with decreased %FEV1 in children.
 - Asthma increased daytime sleepiness in OSA patients.
 - %FEV1 tended to decrease in adult asthma patients complicated with OSA.
 - More severe asthma or difficult-to-control asthma was independently associated with OSA
 - It is strongly recommended that people with moderate-to severe or difficult-to-control asthma screen for OSA and get the appropriate treatment.

Wang et al, Eur. Journal of Medical Research 2023; 28: 139

Asthma → OSA

Impact

- Teodorescu et al Teodorescu et al, JAMA 2015(313)2:157
 - Wisconsin Sleep Cohort Study (1988 onwards)
 - Adults to attend PSG (through 2013) at 4-year intervals
 - 1105 4-year follow-ups by 547 patients (52% women)
 - 466 = non-asthmatic; 81 = asthmatic
 - OSA = AHI >5 in 2 baseline PSGs
 - Incident OSA in 27% asthmatics versus 16% non-asthmatic
 - Asthma also associated with new onset OSA w/ habitual sleepiness
 - **Asthma associated with increased risk of new-onset OSA.**

Asthma → OSA Impact

Table 1. Obstructive Sleep Apnea Burden in Asthma: Epidemiologic and Clinical Studies

Reference	Sample	Assessment and Exclusion of Treated Patients with OSA	Results
Cross-sectional studies			
Community cohorts			
Larsson <i>et al.</i> , 2001 (4)	<i>n</i> = 4,648	OSA*: questionnaire; OSA treatment not specified Asthma: physician diagnosis	<ul style="list-style-type: none"> • ↑ Prevalence of snoring (OR, 1.6[†]) and apnea (OR, 2.3[†]) in asthma
Clinical populations			
Yigla <i>et al.</i> , 2003 (5)	<i>n</i> = 22 Pulmonary clinic	OSA*: PSG; OSA treatment not specified Asthma: PFT diagnosis on long-term oral steroids	<ul style="list-style-type: none"> • 95% (21/22) prevalence of OSA • ↑ RDI in continuous OCS vs. intermittent OCS group (21.4 ± 3.4 vs. 11.1 ± 1.6)
Karachaliou <i>et al.</i> , 2007 (89)	<i>n</i> = 1,501 Primary care	OSA*: self-reported symptoms Asthma: physician diagnosis + spirometry	<ul style="list-style-type: none"> • Asthma diagnosis not associated with OSA symptoms
Auckley <i>et al.</i> , 2008 (90)	<i>n</i> = 177, asthma clinic <i>n</i> = 328, internal medicine clinic	OSA*: Berlin questionnaire Asthma: physician diagnosis + spirometry	<ul style="list-style-type: none"> • ↑ OSA risk in asthma (39% vs. 27%) • No association between asthma severity and OSA risk
Julien <i>et al.</i> , 2009 (3)	<i>n</i> = 52, asthma clinic <i>n</i> = 26, community control group	OSA*: PSG; treated OSA excluded Asthma: physician diagnosis. Severity by spirometry, ACQ, and steroid use	<ul style="list-style-type: none"> • ↑ OSA prevalence: severe asthma 88%, moderate asthma 58%, control 31% (<i>P</i> < 0.001) • ↑ AHI in asthma
Teodorescu <i>et al.</i> , 2009 (27)	<i>n</i> = 244 Pulmonary and asthma clinic	OSA: OSA risk (SA-SDQ); treated OSA excluded Asthma: NAEPP classification severity	<ul style="list-style-type: none"> • Use of ICS ↑ risk of habitual snoring; OR, 1.6[†] • OSA risk positively associated with asthma severity and ICS use
Teodorescu <i>et al.</i> , 2010 (61)	<i>n</i> = 472 Pulmonary and allergy clinic	OSA: OSA risk (SA-SDQ); treated OSA excluded Asthma: physician diagnosis and ACQ	<ul style="list-style-type: none"> • ↑ OSA risk in uncontrolled asthma; OR, 2.9[†]
Williams <i>et al.</i> , 2011 (91)	Asthma, <i>n</i> = 200 No asthma, <i>n</i> = 1,135 Prenatal clinic	OSA*: habitual snoring Asthma: self-report of physician diagnosis	<ul style="list-style-type: none"> • ↑ Habitual snoring before (OR, 2.1[†]) and during (OR, 1.8[†]) pregnancy in asthma

Asthma → OSA Impact

Teodorescu <i>et al.</i> , 2012 (62)	<i>n</i> = 752 Pulmonary and allergy clinic	OSA: SA-SDQ and medical records (diagnosis with PSG); treated OSA excluded Asthma: physician diagnosis	<ul style="list-style-type: none"> • ↑ OSA risk in asthma with persistent day and night symptoms; OR, 1.9[†] • ↑ Risk of PSG-diagnosed OSA in asthma with day symptoms; OR, 2.1[†]
Braido <i>et al.</i> , 2014 (92)	Asthma, <i>n</i> = 740 Asthma and allergic rhinitis, <i>n</i> = 1,201 Primary care	OSA*: STOP-BANG questionnaire Asthma: physician diagnosis and allergic rhinitis questionnaire	<ul style="list-style-type: none"> • ↑ OSA risk in asthma with rhinitis vs. asthma without rhinitis; OR, 1.4[†]
Teodorescu <i>et al.</i> , 2015 (6)	Nonsevere asthma, <i>n</i> = 161 Severe asthma, <i>n</i> = 94 Control, <i>n</i> = 146 Multicenter study	OSA: OSA risk (SA-SDQ); treated OSA excluded Asthma: physician diagnosis, severity by spirometry and inflammatory markers	<ul style="list-style-type: none"> • ↑ SA-SDQ scores in poorly controlled asthma • ↑ Sputum neutrophils associated with higher SA-SDQ

Asthma → OSA Impact

Table 1. (Continued)

Reference	Sample	Assessment and Exclusion of Treated Patients with OSA	Results
Longitudinal studies, population-based cohorts			
Knuiman <i>et al.</i> , 2006 (16)	<i>n</i> = 967 Prospective	Incident OSA*: self-reported habitual snoring Asthma: questionnaire	<ul style="list-style-type: none"> • ↑ Risk of habitual snoring in new-onset asthma; OR, 2.8[†]
Teodorescu <i>et al.</i> , 2015 (17)	No asthma, <i>n</i> = 547 Asthma, <i>n</i> = 81 Prospective	No OSA or PAP use at baseline Incident OSA: PSG AHI > 5 or starting CPAP treatment for OSA Asthma: physician diagnosis	<ul style="list-style-type: none"> • Adjusted RR of incident OSA, 1.4[†] in asthma vs. nonasthma • ↑ Asthma duration (>10 yr) related to increased risk for incident OSA (RR, 1.71[†]) and for clinically significant OSA (OSA + excessive sleepiness; RR, 2.94[†])
Shen <i>et al.</i> , 2015 (12)	<i>n</i> = 38,840 Retrospective, insurance database	Incident OSA*: ICD-9 Asthma: ICD-9	<ul style="list-style-type: none"> • ↑ OSA incidence in asthma vs. nonasthma HR 12.1 vs. 4.8 per 1,000 person-years • ↑ Incidence of OSA with >1 ER visit/yr (HR, 23.8[†]) and with ICS use (HR, 1.3[†])

Definition of abbreviations: ↑ = increased; ACQ = Asthma Control Questionnaire; AHI = apnea-hypopnea index; CPAP = continuous positive airway pressure; ER = emergency room; HR = hazard ratio; ICD = International Classification of Diseases; ICS = inhaled corticosteroid; NAEPP = National Asthma Education and Prevention Program; OCS = oral corticosteroid; OR = odds ratio; OSA = obstructive sleep apnea; PFT = pulmonary function test; PSG = polysomnography; RDI = respiratory disturbance index; RR = relative risk; SA-SDQ = sleep apnea scale of the Sleep Disorders Questionnaire; STOP-BANG = snoring, tiredness, observed apnea, blood pressure, body mass index, age, neck circumference, and gender.

*History of OSA or treatment not specified.

[†]Statistically significant OR, HR, or RR.

OSA → Asthma Pathophysiology

- OSA → GERD (Asthma trigger)

Demeter et al, J. Gastroenterol. 2004; 39: 815–20

- Hypoxia impairs important defenses during sleep
 - Arousal threshold to resistive loading
 - Cough & asthma symptom perception

Hlavac et al, Sleep 2006; 29: 624–31; Eckert et al, Am. J. Respir. Crit. Care Med. 2006; 173: 506–11;
Eckert et al, Am. J. Respir. Crit. Care Med. 2004; 169: 1224–30

- OSA → Persistent upper airway inflammation → CV morbidity & systemic inflammation of Asthma

Li et al, Thorax 2007; 62: 75–9; Ryan et al, Arch. Physiol. Biochem. 2008; 114: 261–6;
Lampinen et al, Allergy 2004; 59: 793–805


OSA → Asthma Pathophysiology

- Stimulation of upper airway during obstructive events vagally mediated bronchoconstriction in asthmatics
 - Worsens BHR through alterations of chemical arousal threshold or thorough resistive loading

Guilleminault et al, *Eur. Respir. J.* 1988; 1: 902–7; Morrison et al, *Respir. Med.* 1991; 85: 285–9

OSA → Asthma Pathophysiology

- OSA, through its features, notably chronic intermittent hypoxia, has been shown to shift the airway inflammatory profile away from T-helper cell type 2 (Th2) pathways, which leads to lung remodeling and airway dysfunction, in a pattern that is less responsive to ICS therapy.
- Asthma control would likely require a step-up in ICS dose and repeated steroid bursts, further raising the risk for or the severity of OSA.



OSA → Asthma Impact

Table 3. Impact of OSA on asthma severity and control.

Author	Year	Sample	Definition of OSA	Findings
<i>Cross sectional</i>				
ten Brinke [62]	2005	n = 136 difficult-to-treat asthma	PSG or history of snoring and daytime sleepiness with frequent apnea periods of >10 s	↑ frequent exacerbation OR 3.4 (1.2–10.4) adjusted for age and asthma duration. ↔ frequent exacerbation after accounting for covariates
Teodorescu [59]	2010	n = 472 outpatient clinic	Sleep Apnea Scale of the Sleep Disorders Questionnaire (high OSA risk vs. without high risk)	↑ uncontrolled asthma in high OSA risk. OR 2.87 (95% CI 1.54–5.32) accounting for covariates
Kim [60]	2013	n = 217 outpatient clinic	Berlin questionnaire (high risk vs. low risk)	↓ asthma specific quality of life score in high OSA risk (vs. low OSA risk) ↔ asthma control
Teodorescu [61]	2013	n = 813 outpatient clinic	PSG	↑ worse asthma severity step (OR 2.91, 95% CI 1.15–7.36) ↑ severe asthma (OR 6.67, 95% CI 1.74–25.56) in older subjects (age 60–75) vs. OR 2.61, 95% CI 1.28–5.33) in younger subjects (age 18–59).
Tay [63]	2016	n = 90 difficult asthma clinic	Berlin questionnaire (high OSA risk vs. low risk)	↔ frequent exacerbation, ACT score, and asthma-specific quality of life accounting for increasing BMI and other comorbid conditions
Ozden Mat [58]	2021	n = 137 outpatient clinic	Berlin questionnaire (high OSA risk vs. low risk)	↑ 7.9 times increased odds of uncontrolled asthma Odds ratio 7.896, 95% CI 2.902–21.487.


OSA → Asthma Impact

Author	Year	Sample	Definition of OSA	Findings
<i>Longitudinal</i>				
Jordan [64]	2015	<i>n</i> = 2445 World Trade Center Health Registry, 10–11 years follow up	Physician-diagnosed OSA	↑ 1.39 and 1.48 times increased risk of poorly controlled asthma and very poorly controlled asthma, respectively, adjusting for covariates
Wang [65]	2016	<i>n</i> = 146 asthma <i>n</i> = 157 no asthma 1 year follow up	PSG	↑ AHI increased risk of severe asthma exacerbations (OR 1.322, 95% CI 1.148–1.523)
Yii [66]	2017	<i>n</i> = 177 Step 4 of GINA treatment ladder 5 years follow up	PSG	↔ severe asthma exacerbation

AHI, apnea hypopnea index; BMI, body mass index; CI, confidence interval; OR, odds ratio; OSA, obstructive sleep apnea; PSG, polysomnography; ↑: increased, ↓: decreased, ↔: unchanged.

Asthma ↔ OSA

Bi-directional Relationship



Alkhalil et al, J Clin Sleep Med 2009;5(1):71-78

Treatment of Asthma/COPD



Respiratory Treatments



AllergyAsthmaNetwork.org
800.878.4403

123 = DOSE INDICATOR G = GENERIC AVAILABLE DISEASE STATES: A = ASTHMA C = COPD

Allergy & Asthma Network is a national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions through outreach, education, advocacy and research.



SHORT-ACTING BETA₂-AGONIST BRONCHODILATORS

relax tight muscles in airways and offer quick relief of symptoms such as coughing, wheezing and shortness of breath for 3-6 hours

ProAir® Digihaler™ 117 mcg albuterol sulfate 123 A	ProAir® HFA 100 mcg albuterol sulfate 123 A G	ProAir® RespiClick® 117 mcg albuterol sulfate inhalation powder 123 A	Proventil® HFA 120 mcg albuterol sulfate A	Ventolin® HFA 90 mcg albuterol sulfate 123 A G	Xopenex® HFA 59 mcg levalbuterol tartrate A G	Arcapta™ Neohaler™ 75 mcg indacaterol inhalation powder C	Serevent® Diskus® 50 mcg salmeterol xinafoate inhalation powder 123 A C		Striverdi® Respimat® 2.5 mcg olodaterol hydrochloride 123 C	
-----------------------------------------------------------------	------------------------------------------------------------	------------------------------------------------------------------------------------	---------------------------------------------------------	-------------------------------------------------------------	------------------------------------------------------------	------------------------------------------------------------------------	--------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------------------	-------------------------------------------------------------------------------------

LONG-ACTING BETA₂-AGONIST BRONCHODILATORS

in airways and offer lasting relief of symptoms such as coughing, wheezing and shortness of breath for at least 12 hours

Alvesco® HFA 80, 160 mcg ciclesonide 123 A	ArmonAir™ RespiClick® 55, 113, 232 mcg fluticasone propionate inhalation powder 123 A	Arnuity® Ellipta® 50, 100, 200 mcg fluticasone furoate inhalation powder A	Asmanex® HFA 100, 200 mcg mometasone furoate 123 A	Asmanex® Twisthaler® 110, 220 mcg mometasone furoate inhalation powder 123 A	Flovent® Diskus® 50, 100, 250 mcg fluticasone propionate inhalation powder 123 A	Flovent® HFA 44, 110, 220 mcg fluticasone propionate 123 A	Pulmicort Flexhaler® 90, 180 mcg budesonide inhalation powder 123 A	QVAR® Redihaler™ 40, 80 mcg beclomethasone dipropionate 123 A
---------------------------------------------------------	----------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------	-----------------------------------------------------------------	-------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------	-------------------------------------------------------------------------	----------------------------------------------------------------------------------	----------------------------------------------------------------------------

COMBINATION MEDICATIONS

contain both inhaled corticosteroid and long-acting beta₂-agonist (LABA)

Advair Diskus® 100/50, 250/50, 500/50 mcg fluticasone propionate and salmeterol inhalation powder 123 A C G	Advair® HFA 45/21, 115/21, 230/21 mcg fluticasone propionate and salmeterol xinafoate 123 A G	AirDuo™ RespiClick® 55/14, 113/14, 232/14 mcg fluticasone propionate and salmeterol inhalation powder 123 A G	Breo® Ellipta® 100/25, 200/25 mcg fluticasone furoate and vilanterol inhalation powder 123 A C	Dulera® 100/5, 200/5 mcg mometasone furoate and formoterol fumarate dihydrate 123 A	Symbicort® 90/4.5, 160/4.5 mcg budesonide and formoterol fumarate dihydrate 123 A C	Wixela™ Inhub™ 100/50, 250/50, 500/50 mcg fluticasone propionate and salmeterol xinafoate (improved generic of Advair Diskus) 123 A C	Anoro® Ellipta® 62.5/25 mcg umeclidinium and vilanterol inhalation powder 123 C	Bevespi Aerosphere® 9/4.8 mcg glycopyrrolate and formoterol fumarate 123 C	Stiolto® RespiMat® 2.5/2.5 mcg tiotropium bromide and olodaterol 123 C	Utibron™ Neohaler® 27.5/15.6 mcg indacaterol and glycopyrrolate inhalation powder C	Trelegy® Ellipta® 100/62.5/25 mcg fluticasone furoate, umeclidinium and vilanterol inhalation powder 123 C
--------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------

MUSCARINIC ANTAGONIST (ANTICHOLINERGIC)

relieve cough, sputum production, wheeze and chest tightness associated with chronic lung diseases

Short-acting Atrovent® HFA 17 mcg ipratropium bromide 123 C	Long-acting Incruse® Ellipta® 62.5 mcg umeclidinium inhalation powder 123 C	Seebri™ Neohaler® 15.6 mcg glycopyrrolate inhalation powder C	Spiriva® HandiHaler® 18 mcg tiotropium bromide inhalation powder C	Spiriva® RespiMat® 1.25, 2.5 mcg tiotropium bromide 123 A C	Tudorza™ Pressair™ 400 mcg aclidinium bromide inhalation powder 123 C	COMBINATION contains muscarinic antagonist and beta ₂ -agonist Short-acting Combivent® RespiMat® 20/100 mcg ipratropium bromide and albuterol 123 C
------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------	---------------------------------------------------------------------------------	--------------------------------------------------------------------------	------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------


BIOLOGICS

target cells and pathways that cause airway inflammation; delivered by injection or IV

Cinqair® reslizumab A	Dupixent® dupilumab A	Fasenra® benralizumab A	Nucala® mepolizumab A	Xolair® omalizumab A
------------------------------------	------------------------------------	--------------------------------------	------------------------------------	-----------------------------------

BRONCHIAL THERMOPLASTY

A minimally invasive procedure that uses mild heat to reduce airway smooth muscle, leading to fewer severe asthma flares, ER visits, and days lost from activities.
www.bforaasthma.com



PDE4 INHIBITORS

ease lung inflammation and reduce exacerbations

Daliresp®
250, 500 mcg roflumilast
C



Reviewed by Dennis Williams, PharmD

©2019 Allergy & Asthma Network

Most Effective Treatment of OSA



**Abundance of literature
available showing CPAP
benefits to treat OSA**

CPAP → Asthma

Table 4. Impact of CPAP therapy on asthma severity and control.

Author	Year	Sample	Study Design	Findings
Lafond [69]	2007	<i>n</i> = 20 OSA and asthma	Prospective, 6 weeks after CPAP therapy	CPAP use 6.7 h/d ↔ airway responsiveness, %FEV1, FEV1/FVC ratio ↑ asthma-specific quality of life
Teodorescu [16]	2012	<i>n</i> = 75 CPAP therapy, OSA and asthma	Cross-sectional	↓ persistent daytime asthma symptoms ↔ persistent nighttime asthma symptoms
Shaarawy [73]	2013	<i>n</i> = 15 uncontrolled asthma and OSA	Prospective, 6 weeks after CPAP therapy	↓ Epworth sleepiness scale ↓ arousal index ↔ % FEV1, %FVC, FEV1/FVC ratio ↔ ACT score
Kauppi [68]	2016	<i>n</i> = 152 CPAP started after asthma treatment	Cross-sectional, survey questionnaire	CPAP use 6.3 h/d, mean 5.7 years. ↓ self-reported asthma severity and ↑ACT score without significant changes in BMI ↓ daily rescue medication use
Serrano-Pariente [71]	2017	<i>n</i> = 99 OSA and asthma	Prospective, before and after 6 months of CPAP	↓ asthma control questionnaire score ↓ % of uncontrolled asthma ↓ % of asthma attacks ↓ GERD symptoms ↓ positive bronchodilation test ↓ FeNO ↑ Asthma control and ↑ quality of life among patients compliant with CPAP (≥4 h/night) vs. noncompliant subjects.

CPAP → Asthma

Shaker [74]	2017	<i>n</i> = 12 OSA and asthma	Prospective, 3 months after CPAP therapy	↓ daytime and nighttime asthma symptoms ↓ GERD symptoms ↓ difficult to control asthma ↓ Epworth sleepiness scale ↑ %FEV1 ↑ FEV1/FVC ratio ↑ sleep efficiency ↓ total sleep time
Ng [72]	2018	<i>n</i> = 17 CPAP group <i>n</i> = 20 control group Nocturnal asthma symptoms and OSA	Randomized controlled trial	CPAP use, 5.0 h/d at 1 month and 5.2 h/d at 3 months ↓ Epworth sleepiness score ↑ asthma specific quality of life ↑ vital domain of quality of life ↔ ACT score ↔ asthma exacerbation rate, spirometry, and airway responsiveness
Cisneros [70]	2023	<i>n</i> = 100 OSA and asthma	Retrospective, before and ≥3 months after CPAP	↑ clinical asthma control ↑ ACT score


ACT, asthma control test; CPAP, continuous positive airway pressure; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea; PSG, polysomnography; ↑: increased, ↓: decreased, ↔: unchanged.

CPAP → Asthma

- Evidence mainly derived from observational studies
- More RCTs are needed to understand the impact of PAP therapy on Asthma control
- Impact of alternative OSA treatment (HNS, dental appliance etc.) on Asthma – only few studies; most with significant limitations


Integrated (OLDOSA) Overlap Syndrome

- COPD \leftrightarrow OSA
- Asthma \leftrightarrow OSA
- OLD (COPD + Asthma) \leftrightarrow OSA = OLDOSA




(OLDOSA) cohort study: 10-year assessment

- 4,980 veterans with an acute hospitalization (Atlanta VA)
 - Asthma, COPD, OSA, overlapping conditions (40%), OR none of these had been diagnosed (60%)




(OLDOSA) cohort study: 10-year assessment




(OLDOSA) cohort study: 10-year assessment

- Asthma, COPD, OSA and their overlap syndromes had very high long-term mortality.




(OLDOSA) cohort study: 10-year assessment

- OSA patients not on PAP therapy had 1.34 times higher risk of death



(OLDOSA) cohort study: 10-year assessment

- OSA patients nonadherent to PAP therapy had 1.78 times higher risk of death



Summary

- Asthma & OSA both are highly prevalent diseases
- OSA ↔ Asthma : Bi-directional relationship
- Moderate-to-Severe or Difficult to control Asthma → OSA workup
- Higher mortality rate for OSA Asthmatics than OSA only or Asthma only
- CPAP therapy reduces mortality in asthmatics OSA patients
 - Adherence to CPAP further helps reducing mortality
- COPD+Asthma+OSA may present an independent clinical category that needs to be studied further
 - Integrated OLDOSA Overlap Syndrome

Recommendations

- Closely look at screening Asthma patients for OSA
 - Especially in patients with higher BMI and more severe form of Asthma
- Clinicians should keep a low threshold to rule out OSA
 - Particularly in elderly/overweight male asthmatics with difficult to control asthma
 - Use STOP-Bang Questionnaire
- Look out for development of Asthma in OSA patients
 - Especially in younger patients, and in patients with co-existing COPD
- Manage both OSA and Asthma simultaneously
 - Coordination of care among providers

Thank You !



Questions?